Power Law company profile

ReGenX Biosciences

Biotech & Life Sciences · Rockville, United States · Founded 2009 · IPO 2015 Thoroughbred

A leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy

Valuation

$307M

Market cap · May/2026

Revenue

$170M

Latest reported FY

Featured in $10B+ revenueThoroughbred · Power Law outcome

Investors

10 investors on ReGenX Biosciences's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 10 investors entered at this stage

QVT Financial LP

Vivo Capital

F-Prime

Sectoral Asset Management

Foresite Capital

Jennison Associates

Perceptive Advisors

Janus Capital Group

Brookside Capital

Venrock

Global footprint

Where ReGenX Biosciences has talent and traffic

Workforce by country

4 countries with
team presence

🇺🇸 United States99.1%

🇳🇱 Netherlands0.4%

🇸🇦 Saudi Arabia0.4%

🇨🇦 Canada0.3%

4 countries shown

Web traffic by country

26K monthly visits
across markets

🇺🇸 United States50%

🏳️ Korea21.5%

🏳️ Republic of8.5%

🇨🇦 Canada5.4%

🇬🇧 United Kingdom3.5%

Top 5 markets shown

Market sentiment

What the market is saying about ReGenX Biosciences

An AI-synthesized read of the highest-engagement posts about ReGenX Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See ReGenX Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles